Abstract:Abstract 4992 Hydroa vacciniform-like lymphoma is an unusual pediatric cutaneous T-cell lymphoma, which rarely involved with adults. Chemotherapy and/or radiotherapy had little or no benefit. Patients may have a response to α-interferon. We report here an adult case with interferon resistant hydroa vacciniform-like lymphoma that has been successfully treated with sirolimus, an mTOR pathway inhibitor. The patient is a thirty-five year old women,she begun with recurrent cutanous rash and small vesicule around her mouth and nose 3 years ago. One year before, the symptoms were exacerbated with obvious vesiculopapular eruption, edematous, blisters, ulcers, scarring and crusts in her face. Scattered vesiculopapular could be seen in her upper chest and extremities accompanied with fever and submandibular lymphadenopathy. Facial skin biopsy showed angiocentric infiltrates from the epidermis to the subjacent dermis. The infiltrate cells showed a cytotoxic T-cell phenotype, with positive TCR gene rearrangement and EBER expression in situ hybridization. EBV serum test showed EBV-IgA and IgG positive, but serum EBV-DNA was negative. Patient was given α-interferon 300 million units, intramuscularlly, two times a week, plus prednisone 30mg per day, orally. Patients9 skin lesions were improved, but present recurrent episodes of papulovesicular eruptions. For the past 3 month patient had a recurrent high fever and exacerbated vesiculopapular eruptions and blisters. Laboratory test showed anemia and neutropenia, serum biochemistry and marrow examination confirmed that a lymphoma associated hematophagocytosis was complicated. Sirolimus was started at an initial dose of 1.5mg, orally, every 12 hours, combined with dexamethasone 10mg/day, intravenously. Three days later the fever begun to resolved and the skin lesion gradually subsided. Two weeks later the skin lesions disappeared and the dose of sirolinmus begun to tapered to 1.0mg, orally, every 12 hours, with prednisone 30mg/day, orally. By three month of follow-up the patient still on stable and be observed. Disclosures: No relevant conflicts of interest to declare.

Oral sirolimus for the treatment of juvenile xanthogranuloma: Report of two pediatric cases

Gorham-Stout Disease Successfully Treated with Sirolimus (rapamycin): a Case Report and Review of the Literature

Clinical and radiological improvement in Gorham-Stout disease after sirolimus treatment

Successful treatment of juvenile polyposis of infancy with sirolimus: a case report

Sirolimus combined with glucocorticoids in the treatment of Kasabach-Merritt phenomenon in a neonate: A case report

Sirolimus As Initial Therapy for Kaposiform Hemangioendothelioma and Tufted Angioma.

Oral Sirolimus for Diffuse Choroidal Hemangioma in Sturge-Weber Syndrome

Clinical Activity of Sirolimus in Classic Kaposi’s Sarcoma Patients: Long-Term Remission of Lesions

Effectiveness of Sirolimus in the Treatment of Complex Lymphatic Malformations: Single Center Report of 56 Cases.

A prospective multicenter study of sirolimus for complicated vascular anomalies

Population Pharmacokinetic Analysis and Dosing Optimization of Sirolimus in Children with Tuberous Sclerosis Complex.

Topical sirolimus in dermatology: a systematic review

Therapy with sirolimus in vascular anomalies: the experience of two Italian centers on 14 pediatric patients

Sirolimus for the Treatment of Progressive Kaposiform Hemangioendothelioma: A Multicenter Retrospective Study

Efficacy Of Initial Sirolimus Therapy For 27 Patients With Intractable Lymphatic Malformations

Sirolimus Combined with Dexamethasone for the Treatment of a Patient with Interferon Resistant Hydroa Vacciniform-Like Lymphoma

Sirolimus experience in adult patients with vascular malformations

Sirolimus Can Increase the Disappearance Rate of Cardiac Rhabdomyomas Associated with Tuberous Sclerosis: A Prospective Cohort and Self-Controlled Case Series Study

Successful sirolimus treatment of spindle cell haemangiomas in a paediatric patient with Maffucci syndrome

Sirolimus for Vincristine-Resistant Kasabach-Merritt Phenomenon: Report of Eight Patients

P18 Giant Periocular Juvenile Xanthogranulomas Treated with Trametinib